An Early Phase study looking at an antibody to a folate receptor that is expressed in a number of different cancers, linked to a drug that can kill cancer cells.

Sponsor: Eisai Ltd

Cancer type: Triple Negative Breast cancer, Endometrial cancer, Non-small cell lung cancer and Ovarian cancers.

MORAb-202 is an experimental drug that works by targeting and attaching itself to cancer tumour cells that have a specific protein called folate receptor alpha on the cell surface. This protein is found typically within Triple Negative Breast cancer, Endometrial cancer, Non-small Cell Lung cancer and Ovarian cancers.

Once MORAb-202 enters the tumour cells it releases a compound called Eribulin, which works by killing and stopping cancer cells from multiplying.

There are three parts to this study.

• Dose Escalation – to determine and identify the highest tolerable safe dose of the study drug, MORAb-202.
• Dose Confirmation – to gather more information on the safety and effectiveness of selected doses of the study drug in participants with endometrial cancer and ovarian cancer.
• Dose Optimisation – to gather more information on the safety and effectiveness of MORAb-202 using different doses and administration schedules and to gather information on whether a short course (3 days) of corticosteroids (drugs such as prednisone/prednisolone or dexamethasone that may reduce inflammation) can decrease the chance of developing interstitial lung disease (inflammation of lungs) that has been noted after treatment with MORAb202.